Search

Your search keyword '"Silvestri, Barbara"' showing total 44 results
Start Over Author "Silvestri, Barbara"
44 results on '"Silvestri, Barbara"'

6. Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status:The INSPECT Experience

Author

Di Prata, Claudia, Mascherini, Matteo, Ross, Alastair Mac Kenzie, Silvestri, Barbara, Kis, Erika, Odili, Joy, Fabrizio, Tommaso, Jones, Rowan Pritchard, Kunte, Christian, Orlando, Antonio, Clover, James, Kumar, Siva, Russano, Francesco, Matteucci, Paolo, Muir, Tobian, Terlizzi, Francesca de, Gehl, Julie, Grischke, Eva Maria, Di Prata, Claudia, Mascherini, Matteo, Ross, Alastair Mac Kenzie, Silvestri, Barbara, Kis, Erika, Odili, Joy, Fabrizio, Tommaso, Jones, Rowan Pritchard, Kunte, Christian, Orlando, Antonio, Clover, James, Kumar, Siva, Russano, Francesco, Matteucci, Paolo, Muir, Tobian, Terlizzi, Francesca de, Gehl, Julie, and Grischke, Eva Maria

Abstract

Electrochemotherapy has been proven to be an efficient treatment for cutaneous metastases of various cancers. Data on breast cancer (BC) patients with cutaneous metastases were retrieved from the INSPECT database. Patients were divided by their receptor status: HER2+, HR+ (ER/PgR+), and TN (triple negative). Groups were similar for histological subtype and location of the nodules. Most patients were previously treated with surgery/systemic therapy/radiotherapy. We found no differences in the three groups in terms of response ratio (OR per patient 86% HER2+, 80% HR+, 76% TN, p = 0.8664). The only factor positively affecting the complete response rate in all groups was small tumor size (<3 cm, p = 0.0105, p = 0.0001, p = 0.0266, respectively). Local progression-free survival was positively impacted by the achievement of complete response in HER2+ (p = 0.0297) and HR+ (p = 0.0094), while overall survival was affected by time to local progression in all groups (p = 0.0065 in HER2+, p < 0.0001 in HR+, p = 0.0363 in TN). ECT treatment is equally effective among groups, despite different receptor status. Response and local tumor control seem to be better in multiple small lesions than in big armor-like lesions, suggesting that treating smaller, even multiple, lesions at the time of occurrence is more effective than treating bigger long-lasting armor-like cutaneous lesions.

Published
2023

7. Efficacy of Electrochemotherapy in Breast Cancer Patients of Different Receptor Status: The INSPECT Experience

Author

Di Prata, Claudia, primary, Mascherini, Matteo, additional, Ross, Alastair MacKenzie, additional, Silvestri, Barbara, additional, Kis, Erika, additional, Odili, Joy, additional, Fabrizio, Tommaso, additional, Jones, Rowan Pritchard, additional, Kunte, Christian, additional, Orlando, Antonio, additional, Clover, James, additional, Kumar, Siva, additional, Russano, Francesco, additional, Matteucci, Paolo, additional, Muir, Tobian, additional, Terlizzi, Francesca de, additional, Gehl, Julie, additional, and Grischke, Eva-Maria, additional

Published
2023
Full Text
View/download PDF

8. Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020)

Author

Bertino, Giulia, primary, Groselj, Ales, additional, Campana, Luca G., additional, Kunte, Christian, additional, Schepler, Hadrian, additional, Gehl, Julie, additional, Muir, Tobian, additional, Clover, James A. P., additional, Quaglino, Pietro, additional, Kis, Erika, additional, Mascherini, Matteo, additional, Bisase, Brian, additional, Pecorari, Giancarlo, additional, Bechara, Falk, additional, Matteucci, Paolo, additional, Odili, Joy, additional, Russano, Francesco, additional, Orlando, Antonio, additional, Pritchard-Jones, Rowan, additional, Moir, Graeme, additional, Mowatt, David, additional, Silvestri, Barbara, additional, Seccia, Veronica, additional, Saxinger, Werner, additional, de Terlizzi, Francesca, additional, and Sersa, Gregor, additional

Published
2022
Full Text
View/download PDF

9. The Future of Fashion: How the Quest for Digitization and the Use of Artificial Intelligence and Extended Reality Will Reshape the Fashion Industry After COVID-19

Author

Silvestri, Barbara

Subjects
covid-19, lcsh:Fine Arts, fashion, virtual reality, lcsh:Visual arts, lcsh:N, lcsh:N1-9211, artificial intelligence, augmented reality
Abstract

The aim of this paper is to analyze how extended reality (formed by virtual and augmented reality), and artificial intelligence are influencing the fashion field. During and after the Covid19 pandemic, a radical shift happened: most activities, from shopping to showrooms and fashion weeks had to move online. While e-commerce was already a consolidated pillar of fashion shopping, it recently started to evolve to achieve through AR (augmented reality) and VR (virtual reality) what customers could before find in physical stores: interesting experiences and sensory stimuli. Online traffic peaked, creating even more room for technology based on artificial intelligence. With its disrupting powers, AI (artificial intelligence) has all the potentialities to take over each step of the fashion value chain. Furthermore, with the quarantine the production of fashion was slowed down by the absence of workers in production sites. Artificial intelligence and automation could be an answer. In this paper AR, VR and AI technologies are analyzed with practical examples on what has happened and is happening in the industry, from a perspective based on the challenges imposed by Covid-19. Results indicate that AR, VR and AI have the potential to become in the near future the norm in the fashion media and technology ecosystem, reinforcing the digitization process of the industry., ZoneModa Journal, V. 10 N. 2 (2020): Moda, Tecnologia e Distanziamento Sociale

Published
2020

10. Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma:The INSPECT experience (2008-2020)

Author

Bertino, Giulia, Groselj, Ales, Campana, Luca G., Kunte, Christian, Schepler, Hadrian, Gehl, Julie, Muir, Tobian, Clover, James A.P., Quaglino, Pietro, Kis, Erika, Mascherini, Matteo, Bisase, Brian, Pecorari, Giancarlo, Bechara, Falk, Matteucci, Paolo, Odili, Joy, Russano, Francesco, Orlando, Antonio, Pritchard-Jones, Rowan, Moir, Graeme, Mowatt, David, Silvestri, Barbara, Seccia, Veronica, Saxinger, Werner, de Terlizzi, Francesca, Sersa, Gregor, Bertino, Giulia, Groselj, Ales, Campana, Luca G., Kunte, Christian, Schepler, Hadrian, Gehl, Julie, Muir, Tobian, Clover, James A.P., Quaglino, Pietro, Kis, Erika, Mascherini, Matteo, Bisase, Brian, Pecorari, Giancarlo, Bechara, Falk, Matteucci, Paolo, Odili, Joy, Russano, Francesco, Orlando, Antonio, Pritchard-Jones, Rowan, Moir, Graeme, Mowatt, David, Silvestri, Barbara, Seccia, Veronica, Saxinger, Werner, de Terlizzi, Francesca, and Sersa, Gregor

Abstract

Introduction: Cutaneous squamous cell carcinoma (cSCC) is a frequent skin cancer with a high risk of recurrence characterized by tumor infiltration and, in advanced cases, a poor prognosis. ECT (electrochemotherapy) is an alternative treatment option for locally advanced or recurrent cSCC that is unsuitable for surgical resection. In this study, we aimed to evaluate the data in the InspECT (International Network for Sharing Practice on ECT) registry of the referral centers and to clarify the indications for the use of ECT as a treatment modality for cSCC. Materials and methods: Patients with primary, recurrent or locally advanced cSCC from 18 European centers were included. They underwent at least one ECT session with bleomycin between February 2008 and November 2020, which was performed following the European Standard Operating Procedures. Results: The analysis included 162 patients (mean age of 80 years; median, 1 lesion/patient). Side effects were mainly local and mild (hyperpigmentation, 11%; ulceration, 11%; suppuration, 4%). The response to treatment per patient was 62% complete and 21% partial. In the multivariate model, intravenous drug administration and small tumor size showed a significant association with a positive outcome (objective response). One-year local progression-free survival was significantly better (p<0.001) in patients with primary tumors (80% (95% C.I. 70%-90%) than in patients with locally advanced disease (49% (95% C.I. 30%-68%). Conclusion: In the present study, ECT showed antitumor activity and a favorable safety profile in patients with complex cSCC for whom there was no widely accepted standard of care. Better results were obtained in primary and small tumors (<3 cm) using intravenous bleomycin administration.

Published
2022

12. Oxycodone Controlled-Release as First-Choice Therapy for Moderate-to-Severe Cancer Pain in Italian Patients: Results of an Open-Label, Multicentre, Observational Study

Author

Silvestri, Barbara, Bandieri, Elena, Del Prete, Salvatore, Ianniello, Giovanni Pietro, Micheletto, Giuseppe, Dambrosio, Mario, Sabbatini, Giovanni, Endrizzi, Luigi, Marra, Alessandro, Aitini, Enrico, Calorio, Angioletta, Garetto, Ferdinando, Nastasi, Giuseppe, Piantedosi, Francovito, Sidoti, Vincenzo, and Spanu, Piergiorgio

Published
2008
Full Text
View/download PDF

16. Invasive neurostimulation

Author

Mercieri, Marco, Arcioni, Roberto, Palmisani, Stefano, Vano, Valentina, Tigano, Sara, Smith, Thomas, Del Fiore, Maria R, Silvestri, Barbara, Al-Kaisy, Adnan, and Martelletti, Paolo

Published
2015
Full Text
View/download PDF

22. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Author

Ridolfi Ruggero, Naglieri Emanuele, Dalla Palma Maurizio, Paccagnella Adriano, Guida Michele, Romanini Antonella, Del Bianco Paola, Chiarion-Sileni Vanna, Silvestri Barbara, Michiara Maria, and De Salvo Gian Luca

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background High-dose interferon alfa-2b (IFNalfa-2b), according to the ECOG 1684 schedule, is the only approved adjuvant treatment for stage III melanoma patients by the FDA and EMEA. However, the risk/benefit profile has been questioned limiting its world-wide use. In the late nineties, the Italian Melanoma Inter-group started a spontaneous randomized clinical trial (RCT) to verify if a more intense, but shorter than the ECOG 1684 regimen, could improve survival without increasing the toxicity profile. The safety analysis in the first 169 patients who completed the treatment is here described. Methods Stage III melanoma patients were randomized to receive IFNalfa-2b 20 MU/m2/d intravenously (IV) 5 days/week × 4 weeks, repeated for three times on weeks 9 to 12, 17 to 20, 25 to 28 (Dose-Dense/Dose-Intense, DD/DI, arm), or IFNalfa-2b 20 MU/m2/d IV 5 days/week × 4 weeks followed by 10 MU/m2 subcutaneously (SC) three times per week × 48 weeks (High Dose Interferon, HDI, arm). Toxicity was recorded and graded, according to the WHO criteria, as the worst grade that occurred during each cycle. Results The most common toxicities in both arms were flu-like and gastrointestinal symptoms, leukopenia, liver and neuro-psichiatric morbidities; with regard to severe toxicity, only leukopenia was statistically more frequent in DD/DI arm than in HDI arm (24% vs 9%) (p = 0.0074), yet, this did not cause an increase in the infection risk. Discontinuation of treatment, due to toxicity, was observed in 13 and 17% of the patients in the DD/DI and HDI arm, respectively. The median actual dose intensity delivered in the DD/DI arm (36.4 MU/m2/week) was statistically higher than that delivered in the HDI arm (30.7 MU/m2/week) (p = 0.003). Conclusion Four cycles of intravenous high-dose IFNalfa-2b can be safely delivered with an increase in the median dose intensity. Efficacy results from this trial are eagerly awaited.

Published
2006
Full Text
View/download PDF

25. Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients.

Author

Weichenthal, Michael, primary, Chiarion-Sileni, Vanna, additional, Hauschild, Axel, additional, Del Bianco, Paola, additional, Trefzer, Uwe, additional, Guida, Michele, additional, Enk, Alexander, additional, Romanini, Antonella, additional, Loquai, Carmen, additional, Ridolfi, Ruggero, additional, Schadendorf, Dirk, additional, Mandala, Mario, additional, Koller, Josef, additional, Silvestri, Barbara, additional, Gogas, Helen, additional, Medici, Michele, additional, Dummer, Reinhard, additional, De Salvo, Gian Luca, additional, and Mohr, Peter, additional

Published
2013
Full Text
View/download PDF

26. Oxycodone Controlled-Release as??First-Choice Therapy for Moderate-to-Severe Cancer Pain in??Italian Patients

Author

Silvestri, Barbara, primary, Bandieri, Elena, additional, Del Prete, Salvatore, additional, Ianniello, Giovanni Pietro, additional, Micheletto, Giuseppe, additional, Dambrosio, Mario, additional, Sabbatini, Giovanni, additional, Endrizzi, Luigi, additional, Marra, Alessandro, additional, Aitini, Enrico, additional, Calorio, Angioletta, additional, Garetto, Ferdinando, additional, Nastasi, Giuseppe, additional, Piantedosi, Francovito, additional, Sidoti, Vincenzo, additional, and Spanu, Piergiorgio, additional

Published
2008
Full Text
View/download PDF

27. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

Author

Chiarion-Sileni, Vanna, primary, Del Bianco, Paola, additional, Romanini, Antonella, additional, Guida, Michele, additional, Paccagnella, Adriano, additional, Dalla Palma, Maurizio, additional, Naglieri, Emanuele, additional, Ridolfi, Ruggero, additional, Silvestri, Barbara, additional, Michiara, Maria, additional, and De Salvo, Gian Luca, additional

Published
2006
Full Text
View/download PDF

28. O-61 “Non progression” is a reliable endpoint of activity in advanced/metastatic NSCLC, when quality of life assessment is the primary endpoint of efficacy

Author

Rosetti, Francesco, primary, Pappagallo, Giovanni L., additional, Marchioro, Giovanni, additional, Barbato, Fiorenza, additional, Bari, Mario, additional, Azzarello, Giuseppe, additional, Sartori, Donata, additional, Silvestri, Barbara, additional, D'Andrea, Mario R., additional, and Vinante, Orazio, additional

Published
2003
Full Text
View/download PDF

30. Lymphoproliferative Disease in Human Peripheral Blood Mononuclear Cell-Injected SCID Mice. IV. Differential Activation of Human Th1 and Th2 Lymphocytes and Influence of the Atopic Status on Lymphoma Development

Author

Coppola, Vincenzo, primary, Veronesi, Arianna, additional, Indraccolo, Stefano, additional, Calderazzo, Francesca, additional, Mion, Marta, additional, Minuzzo, Sonia, additional, Esposito, Giovanni, additional, Mauro, Daniele, additional, Silvestri, Barbara, additional, Gallo, Paolo, additional, Falagiani, Paolo, additional, Amadori, Alberto, additional, and Chieco-Bianchi, Luigi, additional

Published
1998
Full Text
View/download PDF

42. Physical Therapy and the Pulmonary Patient: Aspects of Evaluation and Treatment

Author

Silvestri, Barbara

Subjects
Physical Therapy and the Pulmonary Patient: Aspects of Evaluation and Treatment (Book), Books -- Book reviews
Abstract

Physical Therapy and the Pulmonary Patient: Aspects of Evaluation and Treatment This book, the second issue of Physical Therapy in Health Care, vol 1, focuses on the assessment and treatment [...]

Published
1989

43. Stroke Rehabilitation

Author

Silvestri, Barbara

Subjects
Stroke Rehabilitation (Book) -- Book reviews, Books -- Book reviews
Published
1988

44. Enjoying Life with Emphysema, 2d ed

Author

Silvestri, Barbara

Subjects
Enjoying Life with Emphysema, 2d Ed (Book), Books -- Book reviews
Abstract

Enjoying Life with Emphysema, ed 2 The authors have written a valuable book for patients with chronic obstructive pulmonary disease (COPD) by identifying problems, addressing the management of the problems, [...]

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results